Search research articles
Contact Us
Filters
Showing results (11-20 of 27) with videos related to
Page
of 3
Sort By:
European Journal of Pharmacology
|
July 16, 2011
Antinociceptive activity of α4β2* neuronal nicotinic receptor agonist A-366833 in experimental models of neuropathic and inflammatory pain
Ramakrishna Nirogi, Sugin Lal Jabaris, Pradeep Jayarajan, et al.
Brain Research
|
April 3, 2012
Difference in the norepinephrine levels of experimental and non-experimental rats with age in the object recognition task
Ramakrishna Nirogi, Renny Abraham, Pradeep Jayarajan, et al.
Bioorganic & Medicinal Chemistry Letters
|
November 13, 2012
Design, synthesis and pharmacological evaluation of 4-(piperazin-1-yl methyl)-N₁-arylsulfonyl indole derivatives as 5-HT₆ receptor ligands
Ramakrishna V S Nirogi, Rajeshkumar Badange, Ramasastri Kambhampati, et al.
Biomolecules
|
February 25, 2023
Progress in Investigational Agents Targeting Serotonin-6 Receptors for the Treatment of Brain Disorders
Ramakrishna Nirogi, Pradeep Jayarajan, Anil Shinde, et al.
The American Journal of Cardiology
|
August 2, 2005
Safety of percutaneous transfemoral coronary and peripheral procedures via aortofemoral synthetic vascular grafts
Michael J Gallagher, Simon R Dixon, Robert D Safian, et al.
European Journal of Medicinal Chemistry
|
January 6, 2016
Benzamide derivatives and their constrained analogs as histamine H3 receptor antagonists
Ramakrishna Nirogi, Anil Shinde, Vinaykumar Tiriveedhi, et al.
Behavioural Pharmacology
|
May 31, 2018
SUVN-502, a novel, potent, pure, and orally active 5-HT6 receptor antagonist: pharmacological, behavioral, and neurochemical characterization
Ramakrishna Nirogi, Renny Abraham, Vijay Benade, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 25, 2025
Drug Development
Ramakrishna Nirogi, Renny Abraham, Jyothsna Ravulu, et al.
Journal of Medicinal Chemistry
|
February 7, 2020
Discovery and Development of 3-(6-Chloropyridine-3-yloxymethyl)-2-azabicyclo[3.1.0]hexane Hydrochloride (SUVN-911): A Novel, Potent, Selective, and Orally Active Neuronal Nicotinic Acetylcholine α4β2 Receptor Antagonist for the Treatment of Depression
Ramakrishna Nirogi, Abdul Rasheed Mohammed, Anil K Shinde, et al.
Journal of Psychopharmacology (Oxford, England)
|
February 6, 2021
Histamine 3 receptor inverse agonist Samelisant (SUVN-G3031): Pharmacological characterization of an investigational agent for the treatment of cognitive disorders
Ramakrishna Nirogi, Venkata R Grandhi, Rajesh B Medapati, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 27) with videos related to
Sort By:
Page
of 3
European Journal of Pharmacology
|
July 16, 2011
Antinociceptive activity of α4β2* neuronal nicotinic receptor agonist A-366833 in experimental models of neuropathic and inflammatory pain
Ramakrishna Nirogi, Sugin Lal Jabaris, Pradeep Jayarajan, et al.
Brain Research
|
April 3, 2012
Difference in the norepinephrine levels of experimental and non-experimental rats with age in the object recognition task
Ramakrishna Nirogi, Renny Abraham, Pradeep Jayarajan, et al.
Bioorganic & Medicinal Chemistry Letters
|
November 13, 2012
Design, synthesis and pharmacological evaluation of 4-(piperazin-1-yl methyl)-N₁-arylsulfonyl indole derivatives as 5-HT₆ receptor ligands
Ramakrishna V S Nirogi, Rajeshkumar Badange, Ramasastri Kambhampati, et al.
Biomolecules
|
February 25, 2023
Progress in Investigational Agents Targeting Serotonin-6 Receptors for the Treatment of Brain Disorders
Ramakrishna Nirogi, Pradeep Jayarajan, Anil Shinde, et al.
The American Journal of Cardiology
|
August 2, 2005
Safety of percutaneous transfemoral coronary and peripheral procedures via aortofemoral synthetic vascular grafts
Michael J Gallagher, Simon R Dixon, Robert D Safian, et al.
European Journal of Medicinal Chemistry
|
January 6, 2016
Benzamide derivatives and their constrained analogs as histamine H3 receptor antagonists
Ramakrishna Nirogi, Anil Shinde, Vinaykumar Tiriveedhi, et al.
Behavioural Pharmacology
|
May 31, 2018
SUVN-502, a novel, potent, pure, and orally active 5-HT6 receptor antagonist: pharmacological, behavioral, and neurochemical characterization
Ramakrishna Nirogi, Renny Abraham, Vijay Benade, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 25, 2025
Drug Development
Ramakrishna Nirogi, Renny Abraham, Jyothsna Ravulu, et al.
Journal of Medicinal Chemistry
|
February 7, 2020
Discovery and Development of 3-(6-Chloropyridine-3-yloxymethyl)-2-azabicyclo[3.1.0]hexane Hydrochloride (SUVN-911): A Novel, Potent, Selective, and Orally Active Neuronal Nicotinic Acetylcholine α4β2 Receptor Antagonist for the Treatment of Depression
Ramakrishna Nirogi, Abdul Rasheed Mohammed, Anil K Shinde, et al.
Journal of Psychopharmacology (Oxford, England)
|
February 6, 2021
Histamine 3 receptor inverse agonist Samelisant (SUVN-G3031): Pharmacological characterization of an investigational agent for the treatment of cognitive disorders
Ramakrishna Nirogi, Venkata R Grandhi, Rajesh B Medapati, et al.
Page
of 3